Filtered By:
Drug: Metformin
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 20834 results found since Jan 2013.
Prevalence and association of co-morbidities in diabetic patients along with prescription patterns in Delhi-NCT, India
ConclusionThe number of diabetic population is high in Delhi. It was evident that a significant percentage of diabetic patients suffered from additional diseases that may lead to worsening of the health conditions. Thus, there is an urgent need to educate and spread awareness amongst the masses about the potential benefits of lifestyle modifications like the incorporation of a healthy diet and physical activities. Additionally, continuous and regular tests should be taken to avoid further complications.
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - January 28, 2019 Category: Endocrinology Source Type: research
Obesity, insulin resistance, and type 1 diabetes mellitus
Purpose of review: To summarize recent studies about obesity, insulin resistance, and type 1 diabetes mellitus (T1DM).
Recent findings: Overweight and obesity continue to be prevalent among individuals with T1DM. Obesity rates appear to have reached a plateau among children with T1DM in some parts of the world. The risk for development of T1DM is increased by obesity and may occur at an earlier age among obese individuals with a predisposition. Obesity increases the risk for comorbidities among individuals with T1DM, especially metabolic syndrome, and microvascular and macrovascular diseases. Metformin, glucagon-like pepti...
Source: Current Opinion in Endocrinology, Diabetes and Obesity - June 27, 2015 Category: Endocrinology Tags: DIABETES AND THE ENDOCRINE PANCREAS II: Edited by Peter A. Gottlieb Source Type: research
A comparative study between myo-inositol and metformin in the treatment of insulin-resistant women.
CONCLUSIONS: MYO and MET, associated with life-style, had both significant beneficial effects on serum progesterone and prolactin levels, menstrual cycle disorders and pregnancy rates in patients without severe carbohydrate metabolism malfunctions. Nevertheless, no significant differences were found between the MET and the MYO groups. Significant results in hormone levels and symptoms were reached with the combination of both treatments, whereas fasting serum insulin levels were slightly improved. Furthermore, the body mass index (BMI) was moderately but not significantly higher in MET and MET+MYO group.
PMID: 28724173...
Source: European Review for Medical and Pharmacological Sciences - July 22, 2017 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant mammary tissues of MMTV-erbB-2 transgenic mice
Metformin, an FDA-approved drug for the treatment of Type II diabetes, has emerged as a promising anti-cancer agent. Other biguanide analogs, including buformin and phenformin, are suggested to have similar pr...
Source: Journal of Experimental and Clinical Cancer Research - February 13, 2017 Category: Cancer & Oncology Authors: Amanda B. Parris, Qingxia Zhao, Erin W. Howard, Ming Zhao, Zhikun Ma and Xiaohe Yang Source Type: research
Glibenclamide and metfoRmin versus stAndard care in gEstational diabeteS (GRACES): a feasibility open label randomised trial
Metformin is widely used to treat gestational diabetes (GDM), but many women remain hyperglycaemic and require additional therapy. We aimed to determine recruitment rate and participant throughput in a randomi...
Source: BMC Pregnancy and Childbirth - September 22, 2017 Category: OBGYN Authors: Rebecca M. Reynolds, Fiona C. Denison, Ed Juszczak, Jennifer L. Bell, Jessica Penneycard, Mark W. J. Strachan, Robert S. Lindsay, Claire I. Alexander, Corinne D. B. Love, Sonia Whyte, Fiona Mackenzie, Ben Stenson and Jane E. Norman Tags: Research article Source Type: research
Liraglutide and Metformin alone or combined therapy for type 2 diabetes patients complicated with coronary artery disease
This study is to compare the effects of Liraglutide and Metformin alone or combined treatment on the cardiac function in T2DM patients complicated with CAD.
Source: Lipids in Health and Disease - December 2, 2017 Category: Lipidology Authors: Ying Liu, Xia Jiang and Xin Chen Tags: Research Source Type: research
Diabetes medications and cardiovascular disease: at long last progress
Purpose of review
Although intensive control of hyperglycemia has been proven to decrease the risk of microvascular complications in type 2 diabetes, it has had little apparent effect on reducing cardiovascular complications – the leading cause of mortality in this disease. We review the cardiovascular effects of various glucose-lowering medications, with a particular focus on the recent studies demonstrating clear benefits from members of several drug categories.
Recent findings
Recently, several randomized controlled studies have revealed significant improvements in cardiovascular outcomes from a thiazolidinedione...
Source: Current Opinion in Endocrinology, Diabetes and Obesity - March 1, 2018 Category: Endocrinology Tags: DIABETES AND THE ENDOCRINE PANCREAS I: Edited by David M. Harlan Source Type: research
Metformin Increases PDH and Suppresses HIF-1 Α Under Hypoxic Conditions and Induces Death in Oral Cancer Cells
Objective: The present study aims to investigate the effects of metformin in hypoxic conditions. Specifically, we focused on pyruvate dehydrogenase (PDH), hypoxia-inducible factor 1 α (HIF-1α) levels, and the oral squamous cell carcinoma (OSCC) cell phenotype. Additionally, we investigated a theoretical consequence of metformin treatment.
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - September 1, 2018 Category: ENT & OMF Authors: Talita Antunes Guimar ães, Lucyana Conceição Farias, Carlos Alberto De Carvalho Fraga, Sérgio Henrique Sousa Santos, Alfredo Maurício Batista De Paula, Ricardo Santiago Gomez, André Luiz Sena Guimarães Tags: Oral and Maxillofacial Pathology Source Type: research
Does metformin usage improve survival in head and neck squamous cell carcinoma? A population-based study
We sought to expand upon preliminary data suggesting that metformin confers a survival benefit to patients with head and neck squamous cell carcinoma (HNSCC).
Source: Journal of Otolaryngology - Head and Neck Surgery - December 4, 2018 Category: ENT & OMF Authors: Alexandra E. Quimby, Nicole L. Lebo, Rebecca Griffiths, Stephen Hall, Jim Dimitroulakos and Stephanie Johnson-Obaseki Tags: Original research article Source Type: research
Curcumin combined with metformin decreases glycemia and dyslipidemia, and increases paraoxonase activity in diabetic rats
Combination of current antidiabetic agents with natural antioxidants to manage diabetes mellitus and its complications has appeared as an emerging trend. Curcumin, a yellow pigment isolated from Curcuma longa rhi...
Source: Diabetology and Metabolic Syndrome - April 30, 2019 Category: Endocrinology Authors: Daniela Fernandes Roxo, Carlos Alberto Arcaro, Vania Ortega Gutierres, Mariana Campos Costa, Juliana Oriel Oliveira, Tayra Ferreira Oliveira Lima, Renata Pires Assis, Iguatemy Louren ço Brunetti and Amanda Martins Baviera Tags: Short report Source Type: research
Association between metformin use and disease progression in obese people with knee osteoarthritis: data from the Osteoarthritis Initiative —a prospective cohort study
To examine whether metformin use was associated with knee cartilage volume loss over 4 years and risk of total knee replacement over 6 years in obese individuals with knee osteoarthritis.
Source: Arthritis Research and Therapy - May 24, 2019 Category: Rheumatology Authors: Yuanyuan Wang, Sultana Monira Hussain, Anita E. Wluka, Yuan Z. Lim, Fran çois Abram, Jean-Pierre Pelletier, Johanne Martel-Pelletier and Flavia M. Cicuttini Tags: Research article Source Type: research
Metformin inhibits metastatic breast cancer progression and improves chemosensitivity by inducing vessel normalization via PDGF-B downregulation
Vascular maturity and functionality are closely associated with tumor progression and chemosensitivity. The antidiabetic agent metformin has shown its ability to inhibit tumor angiogenesis in metastatic breast...
Source: Journal of Experimental and Clinical Cancer Research - June 4, 2019 Category: Cancer & Oncology Authors: Ji-Chang Wang, Guang-Yue Li, Bo Wang, Su-Xia Han, Xin Sun, Yi-Na Jiang, Yan-Wei Shen, Can Zhou, Jun Feng, Shao-Ying Lu, Jian-Lin Liu, Mao-De Wang and Pei-Jun Liu Tags: Research Source Type: research
Effects of metformin on metabolism of white and brown adipose tissue in obese C57BL/6J mice
To investigate effects of metformin on the regulation of proteins of white adipose tissue (WAT) and brown adipose tissue (BAT) in obesity and explore the underlying mechanisms on energy metabolism.
Source: Diabetology and Metabolic Syndrome - November 27, 2019 Category: Endocrinology Authors: Tao Yuan, Juan Li, Wei-Gang Zhao, Wei Sun, Shuai-Nan Liu, Quan Liu, Yong Fu and Zhu-Fang Shen Tags: Research Source Type: research
PTPRD-inactivation-induced CXCL8 promotes angiogenesis and metastasis in gastric cancer and is inhibited by metformin
Protein tyrosine phosphatase receptor delta (PTPRD) is frequently inactivated in various types of cancers. Here, we explored the underlying mechanism of PTPRD-loss-induced cancer metastasis and investigated an...
Source: Journal of Experimental and Clinical Cancer Research - December 5, 2019 Category: Cancer & Oncology Authors: Won Jung Bae, Ji Mi Ahn, Hye Eun Byeon, Seokwhi Kim and Dakeun Lee Tags: Research Source Type: research
Metformin-repressed miR-381-YAP-snail axis activity disrupts NSCLC growth and metastasis
Recent evidence indicates that metformin inhibits mammalian cancer growth and metastasis through the regulation of microRNAs. Metformin regulates miR-381 stability, which plays a vital role in tumor progressio...
Source: Journal of Experimental and Clinical Cancer Research - January 6, 2020 Category: Cancer & Oncology Authors: Dan Jin, Jiwei Guo, Yan Wu, Weiwei Chen, Jing Du, Lijuan Yang, Xiaohong Wang, Kaikai Gong, Juanjuan Dai, Shuang Miao, Xuelin Li and Guoming Su Tags: Research Source Type: research
